Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sanofi Licenses Possible Renagel/Renvela Successor From Ardelyx

25 Feb 2014

• By Paul Bonanos

Related Content

Sanofi Claims Genzyme With $20.1 Billion Upfront And CVRs

21 Feb 2011

Genzyme Sees Renagel Clinical Data Driving Sales After Purchase Of GelTex

18 Sep 2000

Amgen’s Phosphate Binder Loss May Be Genzyme’s Gain

28 Jan 2009

Related Companies

Sanofi

Ardelyx Inc.

Amneal Pharmaceuticals, Inc.

Sanofi Genzyme

AstraZeneca PLC

Additional Topics

United States France Europe Deals BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.